
    
      Subjects will be randomised in a 1:1 ratio to receive either SB16 or Prolia速. At Month 12,
      subjects in Prolia速 treatment group will be randomised again in a 1:1 ratio to either
      continue on Prolia速 treatment or be transitioned to SB16 treatment. Investigational product
      (60 mg in 1 mL of SB16 or Prolia速) will be given subcutaneously every 6 months up to Month
      12, and the last assessment will be done at Month 18.
    
  